Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

397 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.
Vande Casteele N, Ferrante M, Van Assche G, Ballet V, Compernolle G, Van Steen K, Simoens S, Rutgeerts P, Gils A, Vermeire S. Vande Casteele N, et al. Among authors: van steen k, van assche g. Gastroenterology. 2015 Jun;148(7):1320-9.e3. doi: 10.1053/j.gastro.2015.02.031. Epub 2015 Feb 24. Gastroenterology. 2015. PMID: 25724455 Clinical Trial.
Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease.
Vermeire S, Louis E, Carbonez A, Van Assche G, Noman M, Belaiche J, De Vos M, Van Gossum A, Pescatore P, Fiasse R, Pelckmans P, Reynaert H, D'Haens G, Rutgeerts P; Belgian Group of Infliximab Expanded Access Program in Crohn's Disease. Vermeire S, et al. Among authors: van assche g, van gossum a. Am J Gastroenterol. 2002 Sep;97(9):2357-63. doi: 10.1111/j.1572-0241.2002.05991.x. Am J Gastroenterol. 2002. PMID: 12358256 Free article.
Optimizing anti-TNF treatment in inflammatory bowel disease.
Rutgeerts P, Van Assche G, Vermeire S. Rutgeerts P, et al. Among authors: van assche g. Gastroenterology. 2004 May;126(6):1593-610. doi: 10.1053/j.gastro.2004.02.070. Gastroenterology. 2004. PMID: 15168370 Review.
C-reactive protein as a marker for inflammatory bowel disease.
Vermeire S, Van Assche G, Rutgeerts P. Vermeire S, et al. Among authors: van assche g. Inflamm Bowel Dis. 2004 Sep;10(5):661-5. doi: 10.1097/00054725-200409000-00026. Inflamm Bowel Dis. 2004. PMID: 15472532 Review.
397 results